2. GPCR/G Protein Stem Cell/Wnt MAPK/ERK Pathway Apoptosis Immunology/Inflammation Neuronal Signaling
  3. Formyl Peptide Receptor (FPR) ERK JNK TNF Receptor Interleukin Related Amyloid-β
  4. Quin-C7

Quin-C7 is an orally active FPR2/ALX antagonist. Quin-C7 binds to the orthosteric ligand-binding pocket of FPR2/ALX, modulates receptor activation, and inhibits pro-inflammatory ERK signaling mediated by serum amyloid A (SAA). Quin-C7 reduces pro-inflammatory mediators TNF-α levels, increases anti-inflammatory IL-10, decreases inflammatory neutrophils and pro-inflammatory M1 macrophages, downregulates ERK1/2 phosphorylation, and upregulates JNK1/2/3 phosphorylation. Quin-C7 blocks FPR2/mFpr2 signaling, reduces brain lesion volume. Quin-C7 can be used for the research of inflammatory bowel disease and neuromyelitis optica spectrum disorder.

For research use only. We do not sell to patients.

Quin-C7

Quin-C7 Chemical Structure

CAS No. : 871100-12-8

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 Customer Validation

Quin-C7 Related Antibodies

Top Publications Citing Use of Products

View All ERK Isoform Specific Products:

View All Isoforms
ERK ERK1 ERK2 ERK5 ERK8

View All JNK Isoform Specific Products:

View All Isoforms
JNK1 JNK2 JNK3 JNK

View All TNF Receptor Isoform Specific Products:

View All Isoforms
TNFRSF1A/CD120a TNFRSF3/CD18 TNFRSF4 TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF7/CD27 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF10B/DR5/CD262 TNFRSF12A/TWEAK TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Quin-C7 is an orally active FPR2/ALX antagonist. Quin-C7 binds to the orthosteric ligand-binding pocket of FPR2/ALX, modulates receptor activation, and inhibits pro-inflammatory ERK signaling mediated by serum amyloid A (SAA). Quin-C7 reduces pro-inflammatory mediators TNF-α levels, increases anti-inflammatory IL-10, decreases inflammatory neutrophils and pro-inflammatory M1 macrophages, downregulates ERK1/2 phosphorylation, and upregulates JNK1/2/3 phosphorylation. Quin-C7 blocks FPR2/mFpr2 signaling, reduces brain lesion volume. Quin-C7 can be used for the research of inflammatory bowel disease and neuromyelitis optica spectrum disorder[1][2].

IC50 & Target[1]

ERK1

 

ERK2

 

JNK1

 

JNK2

 

JNK3

 

IL-10

 

In Vitro

Quin-C7 binds with high affinity to human FPR2/ALX, forming a network of polar and stacking interactions with receptor residues, including a unique hydrogen bond with Q2586.52[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Quin-C7 Related Antibodies
In Vivo

Quin-C7 (0.512-320 mg/kg; I.g.; daily; 7 days) ameliorates DSS (HY-116282C)-induced acute colitis in male C57BL/6N mice with an ED50 of 2.2110 mg/kg for symptomatic DAI improvement, via modulation of myeloid cell activity and ERK/JNK signaling pathways[1].
Quin-C7 (16-32 mg/kg; i.g.; daily; 4 days) significantly reduces pathology in NMOSD mice[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6N (male, SPF grade, 7-8 weeks old, body weight 21 g, DSS-induced acute colitis)[1]
Dosage: 0.512 mg/kg; 2.56 mg/kg; 12.8 mg/kg; 64 mg/kg; 320 mg/kg; 16 mg/kg; 160 mg/kg
Administration: i.g.; daily; 7 days
Result: Reduced weight loss and decreased Disease Activity Index (DAI) compared to vehicle-treated colitis mice.
Showed an ED50 for symptomatic amelioration (DAI loss) was 2.2110 mg/kg, and ED50 for weight recovery was 1.1430 mg/kg.
Reduced colonic tissue damage, immune cell infiltration, and histopathological scores compared to vehicle-treated colitis mice.
Reversed DSS-induced colon shortening compared to vehicle-treated colitis mice.
Reduced colonic TNF-α levels, increased colonic IL-10 levels, and reduced colonic myeloperoxidase (MPO) and Ly6G levels compared to vehicle-treated colitis mice.
Reduced splenic neutrophil (CD45+ CD11b+ Ly6G+) fractions, reduced colonic neutrophil fractions and median Ly6G fluorescence intensity, and reduced colonic F4/80+ CD86+ (M1 macrophage) cell fractions compared to vehicle-treated colitis mice.
Decreased phosphorylation levels of colonic ERK1/2 and increased phosphorylation levels of colonic JNK1/2/3 compared to vehicle-treated colitis mice.
Showed no significant change in colonic p38 phosphorylation.
Animal Model: C57BL/6 (8-10 weeks of age; NMOSD induced by intracerebral infusion of AQP4-IgG and human complement)[2]
Dosage: 16 mg/kg; 32 mg/kg
Administration: i.g.; daily; 4 days
Result: Significantly reduced loss of AQP4, GFAP, and MBP, and brain lesion volume at 32 mg/kg/day.
Reduced the absolute number of B cells and NK cells in the spleen, and the absolute number of microglia and infiltrating CD4+ T cells in the brain.
Increased the percentage of microglia expressing anti-inflammatory factors IL-10 and TGF-β.
Decreased the percentage of microglia expressing pro-inflammatory factors IL-6 and TNF-α.
Molecular Weight

431.48

Formula

C25H25N3O4
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

CCCCOC1=CC=C(C(NN2C(C3=CC=C(C=C3)O)NC4=CC=CC=C4C2=O)=O)C=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (231.76 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.3176 mL 11.5880 mL 23.1760 mL
5 mM 0.4635 mL 2.3176 mL 4.6352 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 5 mg/mL (11.59 mM); Clear solution

    This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 5 mg/mL (11.59 mM); Clear solution

    This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.3176 mL 11.5880 mL 23.1760 mL 57.9401 mL
5 mM 0.4635 mL 2.3176 mL 4.6352 mL 11.5880 mL
10 mM 0.2318 mL 1.1588 mL 2.3176 mL 5.7940 mL
15 mM 0.1545 mL 0.7725 mL 1.5451 mL 3.8627 mL
20 mM 0.1159 mL 0.5794 mL 1.1588 mL 2.8970 mL
25 mM 0.0927 mL 0.4635 mL 0.9270 mL 2.3176 mL
30 mM 0.0773 mL 0.3863 mL 0.7725 mL 1.9313 mL
40 mM 0.0579 mL 0.2897 mL 0.5794 mL 1.4485 mL
50 mM 0.0464 mL 0.2318 mL 0.4635 mL 1.1588 mL
60 mM 0.0386 mL 0.1931 mL 0.3863 mL 0.9657 mL
80 mM 0.0290 mL 0.1449 mL 0.2897 mL 0.7243 mL
100 mM 0.0232 mL 0.1159 mL 0.2318 mL 0.5794 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Quin-C7 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Quin-C7871100-12-8Formyl Peptide Receptor (FPR)ERKJNKTNF ReceptorInterleukin RelatedAmyloid-βExtracellular signal regulated kinasesc-Jun N-terminal kinaseTumor Necrosis Factor ReceptorTNFRILβ-amyloid peptideAβAbetaastrocytesIL-10neuromyelitis optica spectrum disorderinflammatory bowel diseaseformyl peptide receptor 2/ALXmyeloid cellsERK signalingC57BL/6N miceserum amyloid AmicrogliaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Quin-C7
Cat. No.:
HY-W668775
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (254 KB) Français - FR (254 KB) Deutsch - DE (254 KB) Norwegian - NO (254 KB) Español - ES (254 KB) Swedish - SV (254 KB) Italian - IT (254 KB) Korean - KR (254 KB) Portuguese - PT (254 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.